Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects

British Journal of Clinical Pharmacology

Volumn 58, Issue 1, 2004, Pages 40-51

  Guth, Brian D ^a   Narjes, Hans ^a   Schubert, Hans Dieter ^a   Tanswell, Paul ^a   Riedel, Axel ^a   Nehmiz, Gerhard ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Bleeding time; Platelet aggregation; Terbogrel; Thromboxane receptor; Thromboxane synthase

Indexed keywords

ACETYLSALICYLIC ACID; PROSTACYCLIN; TERBOGREL; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; THROMBOXANE RECEPTOR; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA;

6-KETOPROSTAGLANDIN F1 ALPHA; ADULT; ASPIRIN; BLEEDING TIME; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; MALE; PLATELET AGGREGATION; PYRIDINES; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 3142512628     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02083.x     Document Type: Article

References (19)

1. Antiplatelet Trialist Collaboration. Collaborative overview of randomised trials of antiplatelet therapy: 1. Prevention of death, myocardial infarction, and stoke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
2. Cannon CP, CAPRIE investigators. Effectiveness of clopidogrel versus aspirin in preventing acute myocardial infarction in patients with symptomatic atherothrombosis (CAPRIE Trial). Am J Cardiol 2002; 90: 760-2.
3. The EPIC investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
4. The CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
5. Ferguson JJ. Highlights of the 48th Scientific Sessions of the American College of Cardiology. Circulation 1999; 100: 570-5.
6. Newby LK, et al. (The Symphony Investigators). Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 2000; 355: 337-45.
7. The CURE investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronar syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
8. Müller TH, Guth BD. Pharmacological Strategies for antithrombotic therapy. In Systemic cardiac embolism, ed. Ezekowitz MD. Marcel Dekker, New York, Basel, Hong Kong 1994; 97-130.
9. 2/ prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patient with acute myocardial infarction. Circulation 1994; 89: 588-95.
10. Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci 1991; 12: 158-63.
11. 2/prostaglandin endoperoxide receptor blockade combined in one molecule. I. Biochemical profile in vitro. Thromb Haemostas 1989; 61: 35-45.
12. 2 receptor antagonists and synthase inhibitors. J Med Chem 1999; 42: 1235-49.
13. Schepky M. Vergleich der Methoden Simplate I und Precisette zur Bestimmung der Blutungszeit an Probanden. [Comparison of two incision methods, Simplate I and Precisette, on bleeding time in healthy subjects]. Dissertation, Freiburg, 1994.
14. Heinzel G, Woloszczak W, Thomann P. TopFit. Pharmacokinetic and pharmacodynamic data analysis system for the PC, Version 2.0. Stuttgart: Gustav Fischer Verlag, 1993.
15. Mayer PR, Brazzell RK. Application of statistical moment theory to pharmacokinetics. J Clin Pharmacol 1988; 28: 481-3.
16. Cough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/ pharmacokinetics UK joint Working Party. Drug Information J 1995; 29: 1039-48.
17. Derendorf H, Meibohm B. Modeling of pharmacokinetic/ pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res 1999; 16: 176-84.
18. Narjes H, Nehmiz G. Effect of hospitalization on liver enzymes in healthy subjects. Eur J Clin Pharmacol 2000; 56: 329-33.
19. Schrör K. Antiplatelet drugs. A comparative review. Drugs 1995; 50: 7-28.